Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
246 hedge funds and large institutions have $7.02B invested in Karuna Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 111 increasing their positions, 69 reducing their positions, and 37 closing their positions.
118% more call options, than puts
Call options by funds: $176M | Put options by funds: $80.7M
61% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 69
4% more capital invested
Capital invested by funds: $6.78B → $7.02B (+$242M)
3% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 37
0% less funds holding
Funds holding: 247 → 246 (-1)
17% less funds holding in top 10
Funds holding in top 10: 12 → 10 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$324M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$244M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$106M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$93M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$86.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$92.3M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$57.4M |
| 3 |
Renaissance Technologies
New York
|
-$36.4M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$34.4M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$32.6M |
KRTX Hedge Fund Activity: Q1 2023 in Review
246 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q1 2023, worth a combined $7.02B — up 3.6% from $6.78B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new KRTX positions and 37 closed out — a net gain of 1 holder — while 111 added to existing stakes and 69 trimmed.
The largest buyer was Capital International Investors, adding an estimated $324M. The largest seller was Arch Venture Management, cutting an estimated $92.3M.
- 246 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q1 2023, down from 247 in Q4 2022.
- Funds reported $7.02B of Karuna Therapeutics, Inc. Common Stock stock for Q1 2023, up 3.6% quarter-over-quarter.
- 38 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q1 2023 and 37 closed out, a net change of +1 holder.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q1 2023 was Capital International Investors, an estimated $324M added.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q1 2023 was Arch Venture Management, an estimated $92.3M sold.
Based on aggregated 13F filings for Q1 2023.